370 related articles for article (PubMed ID: 30234487)
21. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
22. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4
An J; Ponthier CM; Sack R; Seebacher J; Stadler MB; Donovan KA; Fischer ES
Nat Commun; 2017 May; 8():15398. PubMed ID: 28530236
[TBL] [Abstract][Full Text] [Related]
23. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
24. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
[TBL] [Abstract][Full Text] [Related]
25. Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.
Zhao M; Hu M; Chen Y; Liu H; Chen Y; Liu B; Fang B
Biochem Biophys Res Commun; 2021 Apr; 549():150-156. PubMed ID: 33676183
[TBL] [Abstract][Full Text] [Related]
26. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418
[TBL] [Abstract][Full Text] [Related]
28. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
29. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex.
Matyskiela ME; Clayton T; Zheng X; Mayne C; Tran E; Carpenter A; Pagarigan B; McDonald J; Rolfe M; Hamann LG; Lu G; Chamberlain PP
Nat Struct Mol Biol; 2020 Apr; 27(4):319-322. PubMed ID: 32251415
[TBL] [Abstract][Full Text] [Related]
31. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
[TBL] [Abstract][Full Text] [Related]
32. The novel mechanism of lenalidomide activity.
Fink EC; Ebert BL
Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
[TBL] [Abstract][Full Text] [Related]
33. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
34. Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Gao S; Geng C; Song T; Lin X; Liu J; Cai Z; Cang Y
J Biol Chem; 2017 Mar; 292(9):3683-3691. PubMed ID: 28087699
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL
Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937
[TBL] [Abstract][Full Text] [Related]
36. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
[TBL] [Abstract][Full Text] [Related]
37. CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
Fu SJ; Hu MC; Peng YJ; Fang HY; Hsiao CT; Chen TY; Jeng CJ; Tang CY
Cells; 2020 May; 9(6):. PubMed ID: 32466489
[TBL] [Abstract][Full Text] [Related]
38. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
[TBL] [Abstract][Full Text] [Related]
40. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]